Evidence map›Paper›PMID 40863730›Full record

ArticleAntimicrobial agents and chemotherapy2025

Fostemsavir analog BMS-818251 has enhanced viral neutralization potency and similar escape mutation profile.

Yen-Ting Lai, Adam S Dingens, Megan DeMouth, Sabrina Helmold Hait, Sijy O'Dell, Arne Schon, Adam S Olia, Tao Wang, Hannah R Shrader, Sarah E Lovelace and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Yen-Ting Lai *Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.ORCID 0000-0003-3700-6417
Adam S Dingens *Basic Sciences Division and Computational Biology Program, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Megan DeMouthVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Sabrina Helmold HaitVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Sijy O'DellVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Arne SchonDepartment of Biology, Johns Hopkins University, Baltimore, Maryland, USA.
Adam S OliaVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Tao WangDepartment of Discovery Chemistry, Bristol-Myers Squibb Research and Development, Cambridge, Massachusetts, USA.
Hannah R ShraderVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Sarah E LovelaceVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Amarendra PeguVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Nicole A Doria-RoseVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
John R MascolaVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Jesse D BloomBasic Sciences Division and Computational Biology Program, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.ORCID 0000-0003-1267-3408
Peter D KwongVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.ORCID 0000-0003-3560-232X

Funding

amfAR, The Foundation for AIDS Research 109861-61-RKNT
6 · The paper itself

Abstract

BMS-818251, a fostemsavir analog, is a next-generation HIV-1 attachment inhibitor with enhanced potency and a similar resistance profile. By using

Indexed as

Anti-HIV AgentsOrganophosphatesPiperazinesBinding Sitesenv Gene Products, Human Immunodeficiency VirusHIV-1HIV Envelope Protein gp120HIV InfectionsHumansMutationNeutralization TestsVirus InternalizationAnti-HIV Agentsenv Gene Products, Human Immunodeficiency VirusfostemsavirHIV Envelope Protein gp120OrganophosphatesPiperazinesBMS-818251deep mutational scanningentry inhibitorex vivo neutralizationfostemsavirHIV-1resistance

Identifiers

PMID40863730
PMCPMC12486810

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.